Eric Prinssen

3.8k total citations · 1 hit paper
60 papers, 2.8k citations indexed

About

Eric Prinssen is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Epidemiology. According to data from OpenAlex, Eric Prinssen has authored 60 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cellular and Molecular Neuroscience, 35 papers in Molecular Biology and 11 papers in Epidemiology. Recurrent topics in Eric Prinssen's work include Receptor Mechanisms and Signaling (29 papers), Neurotransmitter Receptor Influence on Behavior (16 papers) and Neuroscience and Neuropharmacology Research (15 papers). Eric Prinssen is often cited by papers focused on Receptor Mechanisms and Signaling (29 papers), Neurotransmitter Receptor Influence on Behavior (16 papers) and Neuroscience and Neuropharmacology Research (15 papers). Eric Prinssen collaborates with scholars based in Switzerland, United States and France. Eric Prinssen's co-authors include Laurent B. Nicolas, Stephen Toovey, Irène Knuesel, Markus Britschgi, Laurie Chicha, Jessica A. Hellings, Michael Bodmer, Scott Schobel, Wouter Koek and Will Spooren and has published in prestigious journals such as NeuroImage, Nature Reviews Drug Discovery and Scientific Reports.

In The Last Decade

Eric Prinssen

59 papers receiving 2.8k citations

Hit Papers

Maternal immune activation and abnormal brain development... 2014 2026 2018 2022 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Maternal immune activation and abnormal brain development across CNS disorders
    2014 631 citations Irène Knuesel, Laurie Chicha et al. Nature Reviews Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Prinssen Switzerland 25 1.2k 1.0k 374 370 314 60 2.8k
Irina N. Krasnova United States 33 1.9k 1.6× 1.2k 1.2× 415 1.1× 388 1.0× 296 0.9× 59 3.4k
David Engblom Sweden 32 1.2k 1.0× 1.1k 1.1× 329 0.9× 363 1.0× 277 0.9× 74 3.7k
Qiaoping Yuan United States 35 820 0.7× 1.3k 1.3× 163 0.4× 285 0.8× 224 0.7× 63 3.3k
Sulie L. Chang United States 29 929 0.8× 1.0k 1.0× 388 1.0× 198 0.5× 145 0.5× 136 3.0k
Scott E. Hemby United States 34 2.0k 1.7× 2.0k 1.9× 231 0.6× 490 1.3× 225 0.7× 75 4.5k
Przemysław Bieńkowski Poland 31 1.5k 1.3× 842 0.8× 182 0.5× 557 1.5× 187 0.6× 177 3.2k
Anton Bespalov Russia 33 2.1k 1.8× 1.3k 1.3× 314 0.8× 560 1.5× 229 0.7× 122 3.2k
Svetlana А. Ivanova Russia 29 813 0.7× 737 0.7× 530 1.4× 398 1.1× 126 0.4× 237 3.2k
Subramaniam Jayanthi United States 37 2.2k 1.9× 1.7k 1.6× 341 0.9× 305 0.8× 177 0.6× 80 4.0k
Enrico Domenici Italy 32 699 0.6× 1.6k 1.6× 828 2.2× 400 1.1× 292 0.9× 84 4.1k

Countries citing papers authored by Eric Prinssen

Since Specialization
Citations

This map shows the geographic impact of Eric Prinssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Prinssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Prinssen more than expected).

Fields of papers citing papers by Eric Prinssen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Prinssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Prinssen. The network helps show where Eric Prinssen may publish in the future.

Co-authorship network of co-authors of Eric Prinssen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Prinssen. A scholar is included among the top collaborators of Eric Prinssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Prinssen. Eric Prinssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hipp, Joerg F., Frédéric Knoflach, Robert A. Comley, et al.. (2021). Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. Scientific Reports. 11(1). 7700–7700. 24 indexed citations
2.
Borroni, Edilio, Bernd Bohrmann, Fiona Grueninger, et al.. (2017). Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease. Journal of Pharmacology and Experimental Therapeutics. 362(3). 413–423. 75 indexed citations
3.
Bespalov, Anton, Thomas Steckler, Bruce M. Altevogt, et al.. (2016). Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nature Reviews Drug Discovery. 15(7). 516–516. 56 indexed citations
4.
Bruni, Giancarlo N., Andrew J. Rennekamp, Matthew N. McCarroll, et al.. (2016). Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds. Nature Chemical Biology. 12(7). 559–566. 111 indexed citations
5.
Bruns, Andreas, Thomas Mueggler, Basil Künnecke, et al.. (2015). “Domain gauges”: A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats. NeuroImage. 112. 70–85. 14 indexed citations
6.
Ellenbroek, Bart & Eric Prinssen. (2014). Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?. Behavioural Pharmacology. 26(1 and 2 - Special Issue). 33–44. 22 indexed citations
7.
Knuesel, Irène, Laurie Chicha, Markus Britschgi, et al.. (2014). Maternal immune activation and abnormal brain development across CNS disorders. Nature Reviews Neurology. 10(11). 643–660. 631 indexed citations breakdown →
8.
Reiss, David J., Eric Prinssen, Jürgen Wichmann, Brigitte L. Kieffer, & Abdel‐Mouttalib Ouagazzal. (2012). The nociceptin orphanin FQ peptide receptor agonist, Ro64-6198, impairs recognition memory formation through interaction with glutamatergic but not cholinergic receptor antagonists. Neurobiology of Learning and Memory. 98(3). 254–260. 7 indexed citations
9.
Toovey, Stephen, Eric Prinssen, Craig R. Rayner, et al.. (2012). Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review. Advances in Therapy. 29(10). 826–848. 31 indexed citations
10.
Goeldner, Celia, Will Spooren, Jürgen Wichmann, & Eric Prinssen. (2012). Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair. Psychopharmacology. 222(2). 203–214. 25 indexed citations
11.
Poirier, Agnès, Sara Belli, Christoph Funk, et al.. (2012). Role of the Intestinal Peptide Transporter PEPT1 in Oseltamivir Absorption: In Vitro and In Vivo Studies. Drug Metabolism and Disposition. 40(8). 1556–1565. 14 indexed citations
12.
Shi, Deshi, Dongfang Yang, Eric Prinssen, Brian E. Davies, & Bingfang Yan. (2011). Surge in Expression of Carboxylesterase 1 During the Post-neonatal Stage Enables a Rapid Gain of the Capacity to Activate the Anti-influenza Prodrug Oseltamivir. The Journal of Infectious Diseases. 203(7). 937–942. 50 indexed citations
13.
Parrott, Neil, Brian E. Davies, Gerhard Hoffmann, et al.. (2011). Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants. Clinical Pharmacokinetics. 50(9). 613–623. 87 indexed citations
14.
Lindemann, Lothar, Georg Jaeschke, Aubin Michalon, et al.. (2011). CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 339(2). 474–486. 91 indexed citations
15.
Uchimura, Naohisa, Hiroo Kuwahara, Yuji Kumagai, et al.. (2011). Absence of Adverse Effects of Oseltamivir on Sleep: A Double-Blind, Randomized Study in Healthy Volunteers in Japan. Basic & Clinical Pharmacology & Toxicology. 109(4). 309–314. 1 indexed citations
16.
Nicolas, Laurent B., Cristina Lopez‐Lopez, Laura H. Jacobson, et al.. (2010). Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats. Psychopharmacology. 211(2). 197–208. 14 indexed citations
17.
Ko, Mei‐Chuan, James H. Woods, William E. Fantegrossi, et al.. (2009). Behavioral Effects of a Synthetic Agonist Selective for Nociceptin/Orphanin FQ Peptide Receptors in Monkeys. Neuropsychopharmacology. 34(9). 2088–2096. 80 indexed citations
18.
Bardin, Laurent, Agnès L. Auclair, Mark S. Kleven, et al.. (2007). Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural Pharmacology. 18(2). 103–118. 38 indexed citations
19.
Ceccarelli, Simona, Georg Jaeschke, Bernd Buettelmann, et al.. (2006). Rational design, synthesis, and structure–activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure. Bioorganic & Medicinal Chemistry Letters. 17(5). 1302–1306. 20 indexed citations
20.
Prinssen, Eric, Wouter Koek, & Mark S. Kleven. (2000). The effects of antipsychotics with 5-HT2C receptor affinity in behavioral assays selective for 5-HT2C receptor antagonist properties of compounds. European Journal of Pharmacology. 388(1). 57–67. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irina N. Krasnova Breakdown of academic impact, for papers by David Engblom Breakdown of academic impact, for papers by Qiaoping Yuan Breakdown of academic impact, for papers by Sulie L. Chang Breakdown of academic impact, for papers by Scott E. Hemby Breakdown of academic impact, for papers by Przemysław Bieńkowski Breakdown of academic impact, for papers by Anton Bespalov Breakdown of academic impact, for papers by Svetlana А. Ivanova Breakdown of academic impact, for papers by Subramaniam Jayanthi Breakdown of academic impact, for papers by Enrico Domenici
Rankless by CCL
2026